Erasca Inc (ERAS) Gagner

Erasca, Inc. is a clinical stage precision oncology company. The company is headquartered in San Diego, California and currently employs 103 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.